 | |
| Clinical data | |
|---|---|
| Other names | RU-2420; 7α,17α-Dimethyltrenbolone; 7α,17α-Dimethyl-δ9,11-19-nortestosterone; 7α,17α-Dimethylestra-4,9,11-trien-17β-ol-3-one |
| Routes of administration | By mouth |
| Drug class | Androgen;Anabolic steroid;Progestogen |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H26O2 |
| Molar mass | 298.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dimethyltrienolone (developmental code nameRU-2420) is asynthetic,orally active, and extremelypotentanabolic–androgenic steroid (AAS) and17α-alkylated19-nortestosterone (nandrolone)derivative which was never marketed formedical use.[1] It has among the highest knownaffinity of any AAS for theandrogen (andprogesterone)receptors,[2][3] and has been said to be perhaps the most potent AAS to have ever been developed.[1]
Dimethyltrienolone is an extremely potentagonist of theandrogen andprogesterone receptors and hence AAS andprogestogen.[1] Inanimalbioassays, it was shown to possess more than 100 times theanabolic andandrogenicpotency of the reference AASmethyltestosterone.[1] The drug is not asubstrate for5α-reductase and so is not potentiated or inactivated in so-called "androgenic"tissues like theprostate gland orskin.[1] It is also not a substrate foraromatase and so has noestrogenic activity.[1] Due to its lack of estrogenicity, dimethyltrienolone has no propensity for causing estrogenicside effects likegynecomastia.[1] Because of its C17αmethyl group and very high resistance tohepaticmetabolism, dimethyltrienolone is said to be exceedinglyhepatotoxic.[1]
| Compound | Chemical name | PRTooltip Progesterone receptor | ARTooltip Androgen receptor | ERTooltip Estrogen receptor | GRTooltip Glucocorticoid receptor | MRTooltip Mineralocorticoid receptor | ||
|---|---|---|---|---|---|---|---|---|
| Testosterone | T | 1.0 | 100 | <0.1 | 0.17 | 0.9 | ||
| Nandrolone | 19-NT | 20 | 154 | <0.1 | 0.5 | 1.6 | ||
| Trenbolone | ∆9,11-19-NT | 74 | 197 | <0.1 | 2.9 | 1.33 | ||
| Trestolone | 7α-Me-19-NT | 50–75 | 100–125 | ? | <1 | ? | ||
| Normethandrone | 17α-Me-19-NT | 100 | 146 | <0.1 | 1.5 | 0.6 | ||
| Metribolone | ∆9,11-17α-Me-19-NT | 208 | 204 | <0.1 | 26 | 18 | ||
| Mibolerone | 7α,17α-DiMe-19-NT | 214 | 108 | <0.1 | 1.4 | 2.1 | ||
| Dimethyltrienolone | ∆9,11-7α,17α-DiMe-19-NT | 306 | 180 | 0.1 | 22 | 52 | ||
| Values are percentages (%). Referenceligands (100%) wereprogesterone for thePRTooltip progesterone receptor,testosterone for theARTooltip androgen receptor,estradiol for theERTooltip estrogen receptor,DEXATooltip dexamethasone for theGRTooltip glucocorticoid receptor, andaldosterone for theMRTooltip mineralocorticoid receptor. | ||||||||
Dimethyltrienolone, also known as 7α,17α-dimethyl-δ9,11-19-nortestosterone or as 7α,17α-dimethylestra-4,9,11-trien-17β-ol-3-one, as well as 7α,17α-dimethyltrenbolone, is asyntheticestranesteroid and a17α-alkylatedderivative ofnandrolone (19-nortestosterone).[1] It is the 7α,17α-dimethyl derivative oftrenbolone and the 7α-methyl derivative ofmetribolone,[6] as well as the δ9,11analogue ofmetribolone and the δ9,11, 17α-methylated derivative oftrestolone.[1]
Dimethyltrienolone was first described in 1967.[1][7] It was never marketed for medical use.[1]
